Reckitt Benckiser Group is set to offload its Dermicool heat rash treatment to India’s Emami Limited for INR4.32bn ($56.8m).
The divestment of Dermicool follows the sale of brands such as the Scholl foot-care line and E45 skin-care range and...
Reckitt Divests Dermicool To India's Emami
Listen to this article
Reckitt will divest heat rash treatment Dermicool to India's Emami as it continues to reshape its portfolio around brands with higher growth potential.
Explore how consumer health is evolving. On the go.
More from Asia
- • By
A round-up of the latest global health and wellness moves: Nestlé and Dr Reddy's name JV head; Be-sup hires comms and regulatory director; Ascendis Health appoints interim CFO.
- • By
Mentholatum says two line extensions made with 2% salicylic acid and its "Oxy for Every Kind of Ne" campaign reinforce the brand’s “commitment to tackling every type of acne—from face-ne and chin-ne to body-ne.”
- • By
Request to recall eye drops should be fulfilled promptly and businesses providing lip balms as promotional products must verify contract manufacturers are compliant, recent FDA warnings states. Additional letters went to Jordanian firm about testing alcohol for methane and to a Chinese firm advised that compliance with China’s quality control standards isn’t sufficient.
- • By
Round-up of the latest appointments in the health and wellness markets outside the US: Bayer names joint LATAM/APAC president; Haleon adds directors to board; Bionorica hires global marketing head.
More from Geography
- • By
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
- • By
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
- • By
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
